Physicians' Academy for Cardiovascular Education

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA

Machine learning program predicts that drinking more coffee lowers risk of CVD and stroke

Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Laura M Stevens - Aurora, CO, USA

Possible approaches in precision medicine for secundary CV prevention

Aug. 30, 2016 - ESC Rome, Italy - Dr. Noel Bairey Merz (Los Angeles, CA, USA)

Targeting residual inflammatory risk as a strategy to lower CV risk

Aug. 29, 2016 - ESC Rome, Italy - Prof. Paul Ridker (Boston, MA, USA)
##SCROLLER_ITEMS_FULL_TITLE##

CPAP treatment of OSA neutral on CV endpoints but beneficial for quality of life

Oct. 4, 2016 - ESC - 2016 Rome - Prof Doug McEvoy, MD (Adelaide Institute for Sleep Health, Flinders University, Adelaide, Australia)

Surviving elevated Lp(a): a patient story from diagnosis to treatment

May 27, 2016 - Innsbruck, Germany - Sandra Revill Tremulis, MBA - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

How to treat residual inflammatory risk?

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Paul Ridker, MD - Boston, MA, USA

Elucidating the role of gut microbes in CVD may provide future therapeutic strategies

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Stanley L. Hazen, MD, PhD - Cleveland, OH, USA
##SCROLLER_ITEMS_FULL_TITLE##

HOPE-3 trial suggests that statin therapy is beneficial even in low-risk populations

May 16, 2016 - Dubai, United Arab Emirates - Kausik Ray, MD (Imperial College, London, UK)
##SCROLLER_ITEMS_FULL_TITLE##

BP-lowering medication should not be used in normotensive primary prevention population at intermediate CV risk

May 10, 2016 - ACC 2016, Chicago, IL, USA - Eva Lonn (Hamilton, ONT, Canada)
##SCROLLER_ITEMS_FULL_TITLE##

The EMPA REG Outcome trial: The challenge for cardiologists in managing T2DM

May 10, 2016 - David Fitchett, MD, University of Toronto, Canad
##SCROLLER_ITEMS_FULL_TITLE##

Stroke reduction with PPAR-Y antagonist pioglitazone

May 6, 2016 - Dubai, UAE - Dr Robert J Chilton
##SCROLLER_ITEMS_FULL_TITLE##

HOPE-3: Statin therapy works in everybody with intermediate-risk

Apr. 8, 2016 - Salim Yusuf MD, McMaster University, Hamilton, Ontario
##SCROLLER_ITEMS_FULL_TITLE##

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt
##SCROLLER_ITEMS_FULL_TITLE##

Diabetes & Cardiovascular Disease:The risk factor to be challenged

Sep. 27, 2015
##SCROLLER_ITEMS_FULL_TITLE##

Statins are enough for the prevention of CVD

May 24, 2015 - ISA2015, Amsterdam - Prof Kausik Ray
##SCROLLER_ITEMS_FULL_TITLE##

Lipid Management: diagnostics and guidelines

May 24, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof Kausik Ray
##SCROLLER_ITEMS_FULL_TITLE##

How to manage statin-intolerant patients?

June 11, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Erik Stroes
##SCROLLER_ITEMS_FULL_TITLE##

Lipids: Who is at real high risk?

May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof Kausik Ray
##SCROLLER_ITEMS_FULL_TITLE##

CV Risk management in Russia

Dec. 3, 2014 - Moscow - Prof Andrey Susekov

CVRM Dubai

Sep. 15, 2014
##SCROLLER_ITEMS_FULL_TITLE##

New British guidelines and risk calculator on CV Risk (JBS3)

Apr. 7, 2014 - ACC 2014 - Prof John E Deanfield

CV Risk Master Class Latin American chapter

Nov. 25, 2013

CV Risk Master Class

Oct. 14, 2013

Online CV Risk Master Class

Oct. 21, 2013

Online CV Risk Master Class - Español

Oct. 31, 2013

CardioVascular Risk Master Class

May 17, 2013

CardioVascular Risk Master Class

May 17, 2013

CV Risk Master Class - Asian chapter

May 29, 2013

Guideline differences regarding statin treatment affect ASCVD event prevention

Jan. 17, 2018 - Mortensen MB and Nordestgaard BG. - Ann Intern Med 2018
Statin eligibility differs substantially in the 5 major guidelines, and this impacts on the potential prevention of ASCVD events, which is a function of the number of eligible persons for statin therapy.

Statin eligibility differs substantially in the 5 major guidelines, and this impacts on the potential prevention of ASCVD events, which is a function of the number of eligible persons for statin therapy.

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA
Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.

Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.

Differential associations seen between Lp(a) levels and stroke, depending on AF-status

Jan. 9, 2018 - Aronis KN et al., - J Am Heart Assoc. 2017

In a prospective community-based cohort, Lp(a) ≥50 mg/dL was associated with higher stroke risk in those without AF, but not in those with AF, nor with an elevated risk of AF.

Time to better counteract the anti-statin lobby, to prevent unnecessary harm to patients

Jan. 4, 2018 - news

Following a TV program on the French-German public network ARTE that denied the proven link between cholesterol levels and CVD, the potential effects of such disinformation are considered.

ESC/EAS statin eligibility criteria in primary prevention should include very high TG levels

Nov. 29, 2017 - Madsen CM et al., - Eur Heart J 2017

In a large population-based study, high TG levels identified individuals at high CVD risk, who would not be definite eligible for statin treatment according to the 2016 ESC/EAS guidelines.

Machine learning program predicts that drinking more coffee lowers risk of CVD and stroke

AHA 2017 - Anaheim, CA, USA

Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Laura M Stevens - Aurora, CO, USA
Laura Stevens presented her poster on using artificial intelligence to identify risk factors for CVD and stroke. The found association with coffee was validated with traditional analyses.

AHA 2017 Laura Stevens presented her poster on using artificial intelligence to identify risk factors for CVD and stroke. The found association with coffee was validated with traditional analyses.

Targeting IL-1beta to lower inflammation and thereby CV events proved sensible

Oct. 31, 2017 - Peter Libby - J Am Coll Cardiol. 2017

This review summarizes the rationale to specifically target IL-1beta to lower residual inflammatory risk, now shown to be effective in the CANTOS trial. Other potential targets are also discussed.

Lipid parameters strongly depend on age and sex

Oct. 16, 2017 - Balder JW et al., - J Clin Lipidol. 2017

Based on data of the large Dutch Lifelines cohort, reference values have been developed for lipid parameters.

Skipping breakfast associated with more atherosclerosis

Oct. 9, 2017 - Uzhova I et al. - J Am Coll Cardiol 2017

Skipping breakfast was associated with a higher risk of non-coronary and generalized atherosclerosis in a sample of asymptomatic individuals in thee prospective PESA study

Intensive BP control benefits diabetic patients at high CV risk

Oct. 5, 2017 - Buckley LF et al. - Diabetes Care 2017;

In a SPRINT-eligible ACCORD-BP population, a high-risk cohort of diabetic patients, intensive BP control at a goal of <120 mmHg, reduced CVD outcomes.

AHA Scientific Statement cautiously suggests that meditation may help CV risk reduction

A Scientific Statement From the American Heart Association

Oct. 5, 2017 - news

Based on current evidence – mostly of modest methodological quality – AHA concludes that meditation, given its low costs and low risk, may be an adjunct to conventional CV risk reduction approaches.

Aspirin discontinuation in CVD prevention is associated with increased CV risk

Oct. 2, 2017 - Sundström J et al. - Circulation. 2017

The discontinuation of low-dose long-term aspirin use for CVD prevention in the absence of major surgery or bleeding, was associated with a >30% increased CV risk, shortly after discontinuation.